Our international team highlights issues with efficacy reports in several studies on DMG with the new drug ONC201.
Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting…
Approximately 770 children are diagnosed with cancer in Australia every year. Research has explored their experiences and developed recommendations f…
High-grade gliomas including glioblastoma (GBM) and diffuse midline gliomas (DMG) represent the most lethal and aggressive brain cancers where curren…
Siblings of children with cancer have been shown to experience disruption in multiple domains including family, school, and friendships. Existing lit…
Event-free survival considers other adverse events in addition to mortality. It therefore provides a more complete understanding of the effectiveness…
Delivering cancer control at scale for Aboriginal and Torres Strait Islander communities is a national priority that requires Aboriginal and Torres S…
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear whic…
Invasive fungal disease (IFD) occurs less frequently during treatment for solid compared to hematological malignancies in children, and risk groups a…
The main mission of the Australian and New Zealand Children's Haematology and Oncology Group is to develop and facilitate local access to the world's…